PepGen Advances PGN-EDODM1 to Maximum Planned Dose in Phase II FREEDOM2-DM1 Trial Following Favorable Safety Review
Executive Overview In a major development for the clinical advancement of genetic medicines targeting rare muscle disorders, biotechnology innovator PepGen has announced that an independent Data and Safety Monitoring Board…